Sanofi Common Stock Net 2010-2024 | SNY
Sanofi common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
- Sanofi common stock net for the quarter ending June 30, 2024 was $2.728B, a 0.93% decline year-over-year.
- Sanofi common stock net for 2023 was $2.738B, a 3.05% increase from 2022.
- Sanofi common stock net for 2022 was $2.657B, a 11.12% decline from 2021.
- Sanofi common stock net for 2021 was $2.99B, a 3.94% increase from 2020.
Sanofi Annual Common Stock Net
(Millions of US $) |
| 2023 |
$2,738 |
| 2022 |
$2,657 |
| 2021 |
$2,990 |
| 2020 |
$2,876 |
| 2019 |
$2,809 |
| 2018 |
$2,947 |
| 2017 |
$2,835 |
| 2016 |
$2,859 |
| 2015 |
$2,899 |
| 2014 |
$3,508 |
| 2013 |
$3,519 |
| 2012 |
$3,412 |
| 2011 |
$3,735 |
| 2010 |
$3,482 |
| 2009 |
$3,678 |
Sanofi Quarterly Common Stock Net
(Millions of US $) |
| 2024-06-30 |
$2,728 |
| 2024-03-31 |
|
| 2023-12-31 |
$2,738 |
| 2023-09-30 |
|
| 2023-06-30 |
$2,753 |
| 2023-03-31 |
|
| 2022-12-31 |
$2,657 |
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$2,835 |
| 2017-09-30 |
|
| 2017-06-30 |
$2,774 |
| 2017-03-31 |
|
| 2016-12-31 |
$2,859 |
| 2016-09-30 |
|
| 2016-06-30 |
$2,908 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$2,900 |
| 2014-06-30 |
$3,624 |
| 2013-06-30 |
$3,479 |
| 2012-06-30 |
$3,398 |
| 2012-03-31 |
$0 |
| 2011-12-31 |
$3,735 |
| 2011-09-30 |
|
| 2011-06-30 |
$3,886 |
| 2011-03-31 |
|
| 2010-12-31 |
$3,482 |
| 2010-09-30 |
|
| 2010-06-30 |
$3,346 |
| 2010-03-31 |
|
| 2009-12-31 |
$3,678 |
| 2009-09-30 |
|
| 2009-06-30 |
$3,584 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$145.556B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
